Isolated myeloid sarcoma of the temporal bone: As the first clinical manifestation of acute myeloid leukemia in a patient of down’s syndrome

Marwah, Nisha; Bhutani, Namita; Budhwar, Archana; Sen, Rajeev

doi:10.1016/j.ijscr.2019.03.027

Cited by 7 publications

(5 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the most sensitive markers are CD43 and lysozyme. Expression of CD117 showed to be associated with poorer outcomes (Marwah et al, 2019). In our particular case, the immunohistochemistry findings were positive for CD117 (c-kit), CD38 and strong patchy for CD45 in the brain biopsy.…”

Section: Discussionmentioning

confidence: 51%

“…Immunohistochemistry is essential in confirming the diagnosis and distinguishing its variants (Struhal et al, 2008). The most frequent markers expressed in MS are CD68KP1 followed by MPO, CD117, CD99, CD43, lysozyme, CD34, CD56 and terminal deoxynucleotidyl transferase (TdT) (Avni and Koren-Michowit, 2011; Marwah et al, 2019). However, the most sensitive markers are CD43 and lysozyme.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Myeloid sarcoma involving the central nervous system as initial presentation of acute myeloid leukemia patient: A case report

Murshid¹,

Hafiz²,

Aljohani³

et al. 2022

View full text Add to dashboard Cite

Extra medullary leukemic infiltration of CNS is extremely rare, and its incidence is 3%. Myeloid sarcoma (MS) of the central nervous system (CNS) is associated with a poor prognosis and has an aggressive course. Most commonly associated with hematopoietic neoplasm and, rarely, occurs in an isolated fashion. Presentation of MS is highly variable, the patient might present with a newly neurological deficit due to mass effect that required neurosurgical consideration, and urgent debulking require as a life-saving measure as in our patients. Despite the controversial area in management of MS involving the CNS, we present a case of acute myeloid leukemia (AML) with MS involving the CNS. Our patient was treated surgically as it was lifesaving since the patient presented with a focal neurological deficit. Our patient was admitted for the whole duration and followed conservatively by a multidisciplinary team (neurosurgery/hematology-oncology and intensivists).Clinical presentations, neuroimaging, immunohistochemical findings, and the prognostic indicators as well as the survival rates, are discussed.

show abstract

Section: Discussionmentioning

confidence: 51%

Section: Discussionmentioning

confidence: 99%

Myeloid sarcoma involving the central nervous system as initial presentation of acute myeloid leukemia patient: A case report

Murshid¹,

Hafiz²,

Aljohani³

et al. 2022

View full text Add to dashboard Cite

show abstract

“…In nearly every case of myeloid sarcomas presenting in the temporal bone found in the literature, the patient complained of a clinical triad of symptoms including ear pain (2–30), hearing loss (2,5–7,9–11,13–15,16–22,24–27,30), and either unilateral or bilateral facial nerve palsy (2,4–6,8,9,11,13–15,17–22,24–26,30,31). Forty-four percent of (18/41) of patients presented with all three of these symptoms while 76% (31/41) presented with at least two.…”

Section: Resultsmentioning

confidence: 99%

Myeloid Sarcoma of the Temporal Bone: A Unique Cause of Hearing Loss, Otalgia, and Facial Nerve Weakness

Zheng

Abdel-Aty

Taylor

et al. 2022

Otology &Amp; Neurotology

View full text Add to dashboard Cite

Objective: To characterize a clinical triad of symptoms associated with myeloid sarcomas of the temporal bone via a review of all previously reported cases. Methods: Case report and Ovid MEDLINE database literature review. Results: A literature search revealed that a clinical triad of hearing loss, otalgia, and facial nerve weakness are commonly associated with this rare presentation of myeloid sarcoma in the temporal bone. 44% (18/41) of patients presented with all three symptoms, while 76% (31/41) presented with at least two. The presence of t(8;21) was reported in nine patients with myeloid sarcomas of the temporal bone.Conclusions: Although myeloid sarcomas are exceedingly rare, it is necessary to consider them as part of the differential diagnosis for patients who might present with middle ear and mastoid opacification on computed tomography (CT) scan, hearing loss, otalgia, and facial nerve palsy. Physicians should maintain a high degree of suspicion in patients with a history of acute myelogenous leukemia (AML), especially if previous cytogenetic analysis revealed a t(8;21).

show abstract

“…Of those, 2,308 were excluded from review, and the remaining 576 full‐text articles were scrutinized for eligibility. After excluding 467 articles, a total of 109 articles published from 1948 to 2019 remained in the final analysis 4–6,9–11,14–116 . This provided a total of 255 individual cases for data extraction.…”

Section: Resultsmentioning

confidence: 99%

Metastatic Disease of the Temporal Bone: A Contemporary Review

et al. 2020

View full text Add to dashboard Cite

Objectives To identify the frequency and primary site of metastatic pathologies to the temporal bone and characterize the associated symptomatology. Methods The MEDLINE, Embase, and Web of Science databases were systematically reviewed according to the PRISMA guidelines to identify all cases of pathologically confirmed distant temporal bone metastases published with English translation until October 2019. Descriptive statistics were performed. Results Out of 576 full‐length articles included for review, 109 met final criteria for data extraction providing 255 individual cases of distant temporal bone metastases. There was a male predominance (54.9%) with median age of 59.0 years (range 2–90). The most common locations of primary malignancy included the breasts (19.6%), lungs (16.1%), and prostate (8.6%). Most tumors were carcinomas of epithelial origin (75.3%) and predominantly adenocarcinoma (49.4%). The commonest metastatic sites encountered within the temporal bone were the petrous (72.0%) and mastoid (49.0%) portions. Bilateral temporal bone metastases occurred in 39.8% of patients. Patients were asymptomatic in 32.0% of cases. Symptomatic patients primarily reported hearing loss (44.3%), facial palsy (31.2%), and otalgia (16.6%) for a median duration of 1 month. Petrous lesions were associated with asymptomatic cases (P = .001) while mastoid lesions more often exhibited facial palsy (P = .026), otalgia (P < .001), and otorrhea (P < .001). Non‐carcinomatous tumors were associated with petrosal metastasis (P = .025) and asymptomatic cases (P = .109). Carcinomatous metastases more often presented with otalgia (P = .003). Conclusions Temporal bone metastasis is uncommon but should be considered in patients with subacute otologic symptoms or facial palsy and history of distant malignancy. Laryngoscope, 131:1101–1109, 2021

show abstract

Isolated myeloid sarcoma of the temporal bone: As the first clinical manifestation of acute myeloid leukemia in a patient of down’s syndrome

Cited by 7 publications

References 8 publications

Myeloid sarcoma involving the central nervous system as initial presentation of acute myeloid leukemia patient: A case report

Myeloid sarcoma involving the central nervous system as initial presentation of acute myeloid leukemia patient: A case report

Myeloid Sarcoma of the Temporal Bone: A Unique Cause of Hearing Loss, Otalgia, and Facial Nerve Weakness

Metastatic Disease of the Temporal Bone: A Contemporary Review

Contact Info

Product

Resources

About